Durability of response in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma.

3003Background: Axi-cel, an anti-CD19 CAR T cell therapy, demonstrated significant clinical benefit and a manageable safety profile for pts with refractory large B cell lymphoma in ZUMA-1 (Neelapu ...